arrow
E

Edmund K. Waller

Emory University
H指数:82
被引数:2.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Modulating the VIP-VIPR pathway reprograms CAR T cells for superior antitumor efficacy in preclinical cancer models

通过调节VIP-VIPR通路重编程CAR T细胞,在预临床癌症模型中实现更优的抗肿瘤效果

2026-07-220
PRE
Hypoxia-driven T cell–macrophage–stromal cross-talk sustains fibrosis in preclinical models of cutaneous chronic graft-versus-host disease

缺氧驱动的T细胞-巨噬细胞-基质细胞串扰维持皮肤慢性移植物抗宿主病预临床模型中的纤维化

2026-07-010
PRE
Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma

CTX110作为异基因CD19靶向CAR-T疗法在复发/难治性B细胞非霍奇金淋巴瘤中的安全性与有效性

2026-05-070
OAAI
Identification and characterization of vasoactive intestinal peptide receptor antagonists with high-affinity and potent anti-leukemia activity

高亲和力及强抗白血病活性的血管活性肠肽受体拮抗剂的鉴定与表征

2025-12-300
OAAI
Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial

Orca-T与异基因造血干细胞移植(PRECISION-T):一项多中心、随机III期试验

Blood
IF23.1
2025-12-160
OAAI
Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia

移植预处理、NPM1突变及FLT3-ITD急性髓系白血病中可测量的微小残留病的影响

2025-07-030
OAAI
Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCL

评估接受tisagenlecleucel治疗的复发/难治性B-ALL和DLBCL患者体内CAR转座子水平的评价

2025-06-260
OAAI
Plasma Cytokine and Chemokine Profiles Predict Efficacy and Toxicity of Anti-CD19 CAR-T Cell Therapy in Large B-Cell Lymphoma

血浆细胞因子和趋化因子谱预测大B细胞淋巴瘤中抗CD19 CAR-T细胞疗法的疗效和毒性

2025-02-200
PRE
Pentostatin Low-Dose TBI Is an Effective Conditioning Regimen That Permits Donor Engraftment in Patients with High Co-Morbidities Undergoing the First Transplant or Prior to a Second Transplant

Pentostatin低剂量TBI是一种有效的预处理方案,可在初次移植或二次移植前允许具有高合并症的患者实现供者植入。

BLOOD
IF23.1
2024-11-050
PRE
Circulating Progenitor Cells and Coronary Collaterals in Chronic Total Occlusion

慢性完全闭塞的循环祖细胞和冠状动脉侧支

2024-07-012
PRE